Peptides, Testosterone & Emerging Recovery Therapies

Why Are These Products Receiving So Much Attention?

Athletes and active patients increasingly encounter advertisements for peptides, hormone “optimization,” and recovery compounds through social media, wellness clinics, online pharmacies, and performance-oriented practices. The claims often include faster tendon or ligament healing, accelerated recovery after surgery, increased muscle, reduced inflammation, or improved longevity.

A biologically plausible mechanism is not the same as proven clinical benefit. Before using any emerging therapy, it is important to ask whether the claimed effect has been demonstrated in well-designed human trials and whether the product has established manufacturing standards, dosing, safety monitoring, and regulatory approval.

  • BPC-157 is a synthetic peptide that has been widely marketed for tendon, ligament, muscle, gastrointestinal, and wound healing. Much of the enthusiasm comes from laboratory and animal research rather than high-quality human musculoskeletal trials.

    At present, there is not adequate human clinical evidence to conclude that BPC-157 improves tendon healing, ligament healing, cartilage restoration, muscle recovery, fracture healing, or recovery after orthopedic surgery. Appropriate orthopedic dosing and long-term safety have not been established.

    FDA has specifically reviewed BPC-157 in the compounding context and has identified limited safety information as well as potential concerns related to immunogenicity, peptide aggregation, impurities, and active-ingredient characterization. In 2026, FDA’s Pharmacy Compounding Advisory Committee again reviewed BPC-157-related bulk substances, underscoring that this remains an investigational area rather than an established orthopedic treatment.

    Current Position: BPC-157 should be considered investigational for musculoskeletal healing. Animal data and anecdotal reports are not sufficient to establish that it is safe or effective for orthopedic recovery in humans.

  • TB-500 is marketed as a peptide that may improve soft-tissue healing, angiogenesis, mobility, and recovery. It is related to thymosin-beta-4 biology, but marketed TB-500 products should not be assumed to have the same evidence, purity, or pharmacology as experimental compounds studied in a laboratory setting.

    Current Position: FDA has reported that it has not identified adequate human exposure data for thymosin-beta-4 fragment products marketed as TB-500 and lacks sufficient information to determine their safety. Evidence demonstrating improved orthopedic healing in humans is inadequate.

  • Other compounds encountered in the wellness and performance market include CJC-1295, ipamorelin, GHRP-2, GHRP-6, MOTS-c, KPV, GHK-Cu, and related agents. Their proposed mechanisms vary and may involve growth-hormone signaling, metabolic pathways, inflammation, or tissue signaling.

    These compounds should not be treated as a single class with a shared safety or efficacy profile. For several, FDA has identified limited human safety information or potential concerns related to immunogenicity, impurities, metabolic effects, or other adverse events. There is not adequate evidence to recommend them routinely for orthopedic healing.

The Problem With Online and Compounded Peptide Products

Even when a peptide has interesting preclinical science, a commercially purchased product introduces additional questions: Is the active ingredient what the label claims? Is the concentration accurate? Was the product manufactured under appropriate quality controls? Is it sterile when injected? Are degradation products or impurities present? These questions matter because peptides are complex molecules and product quality can directly affect safety.

The fact that a product is available through a clinic or compounding pharmacy does not by itself establish FDA approval, orthopedic efficacy, or long-term safety.

Testosterone and Hormonal “Optimization”

Testosterone is an established prescription hormone with important physiologic effects on muscle mass, bone, sexual function, erythropoiesis, and other systems. Testosterone replacement therapy may be medically appropriate for selected patients with clinically confirmed hypogonadism under the supervision of a clinician experienced in hormone management. At present, testosterone is not an established orthopedic healing treatment for otherwise eugonadal patients.

Does Testosterone Accelerate Tendon, Ligament, or Surgical Healing?

There is biologic and research interest in the relationship between hormonal status, muscle preservation, rehabilitation, and recovery after injury or surgery. Correcting a true endocrine deficiency may be important for overall health and rehabilitation. However, there is not sufficient clinical evidence to recommend routine testosterone therapy solely to accelerate tendon, ligament, cartilage, or postoperative healing in patients who do not otherwise have an appropriate medical indication. In fact, recent research by Dr. White and his team has demonstrated a possible association with testosterone replacement therapy and certain post-operative complications following shoulder replacement surgery.

Testosterone Replacement vs Anabolic-Androgenic Steroid Use

Medically supervised testosterone replacement aims to treat a defined hormonal condition. Supraphysiologic testosterone or anabolic-androgenic steroid use for performance enhancement is fundamentally different. Higher-dose androgen exposure carries important systemic risks and should not be conflated with appropriate replacement therapy.

Testosterone products are controlled substances and require medical monitoring. Depending on the patient and formulation, relevant considerations can include blood pressure, hematocrit/polycythemia, thromboembolic risk, prostate and urinary symptoms, fertility suppression, sleep apnea, edema, and medication interactions. Current FDA labeling and indications continue to evolve, so treatment decisions should be made with the clinician managing the patient’s endocrine care.

Patients Already Taking Testosterone

Patients who are already receiving prescribed testosterone should tell their orthopedic surgeon and anesthesia team before surgery. They should not independently stop, increase, or alter therapy in an attempt to improve healing. Perioperative management should be individualized with the prescribing clinician when necessary.

Questions to Ask Before Using an Emerging Recovery Therapy:

  • What is the exact active ingredient and manufacturer?

  • Is this FDA-approved, compounded, or investigational?

  • Is it approved for this specific use?

  • What human studies show benefit for my exact injury or operation?

  • What outcomes improved—and by how much?

  • What are the known short- and long-term risks?

  • How is product purity, sterility, and concentration verified?

  • Could the treatment affect fertility, cardiovascular risk, blood counts, glucose, or other medications?

  • Would using this product violate anti-doping rules if I compete in a tested sport?

Our Perspective

Emerging peptides and hormonal strategies are scientifically interesting, and some may ultimately lead to promising therapies. At present, however, BPC-157, TB-500, and similar recovery peptides should be considered investigational for orthopedic healing. Testosterone should be used for an appropriate medical indication rather than marketed as a routine orthopedic recovery drug.

Our approach is to remain open to innovation while distinguishing early-stage science from established treatment. When stronger human evidence becomes available, our recommendations will change with the evidence.

Selected Evidence

  1. FDA: Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. U.S. Food and Drug Administration (current FDA resource). Direct link — Includes BPC-157, TB-500-related products, ipamorelin and other peptides.

  2. FDA Pharmacy Compounding Advisory Committee: July 2026 Meeting Materials. U.S. Food and Drug Administration (2026). Direct link — FDA review materials for BPC-157, TB-500, KPV and MOTS-c.

  3. FDA Testosterone Information. U.S. Food and Drug Administration (updated 2026). Direct link — Current FDA information on approved testosterone therapy and labeling.

  4. FDA Takes Step Forward on Testosterone Therapy for Men. U.S. Food and Drug Administration (2026). Direct link — Illustrates the evolving regulatory evaluation of testosterone indications.

  5. Testosterone Cypionate Prescribing Information. DailyMed / U.S. National Library of Medicine (current label). Direct link — Official product labeling, indications, contraindications, and warnings.

  6. Preoperative testosterone replacement therapy is associated with increased rates of periprosthetic joint infection, acute kidney injury, and emergency department utilization after total shoulder arthroplasty. Journal of Shoulder and Elbow Surgery (202). Direct Link — Current evidence on the use of TRT around the time of shoulder replacement surgery.